Search Results
- < Prev
1 of 1
- Next >
News Releases
-
May 24, 2013, 11:00 ET
Boston Scientific To Participate In The 38th Annual Deutsche Bank 2013 Healthcare Conference
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston. Mike Mahoney, president and chief executive officer, and Jeff Capello, executive vice president and chief financial officer, will participate...
More news about: Boston Scientific Corporation , Deutsche Bank 2013 Healthcare Conference
-
May 22, 2013, 12:20 ET
New Data Demonstrate Significant And Sustained Blood Pressure Reduction With Boston Scientific Vessix™ Renal Denervation System
Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix™ Renal Denervation System. Data on the first 41 subjects...
More news about: Boston Scientific Corporation , EuroPCR Scientific Program
-
May 22, 2013, 10:41 ET
Boston Scientific Reports Lotus™ Valve System Met Primary Performance Endpoint in REPRISE II Trial
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of the Lotus™ Valve System in symptomatic patients with severe aortic valve disease considered...
More news about: Boston Scientific Corporation , EuroPCR Scientific Program
-
May 22, 2013, 09:13 ET
Boston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the...
More news about: Boston Scientific Corporation , EuroPCR Scientific Program
-
May 21, 2013, 11:46 ET
Boston Scientific Long Term Data Demonstrate Bronchial Thermoplasty Treatment Benefits Persist Out to Five Years in Patients with Severe Asthma
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT) System continues to show therapy benefits in adult patients with severe uncontrolled asthma. ...
More news about: Boston Scientific Corporation , American Thoracic Society
-
May 21, 2013, 05:02 ET
OrbusNeich seizes Boston Scientific stents in Germany as part of patent infringement proceedings
Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") today announced that it has enforced the seizure of over 190 stent systems from Boston Scientific Corporation (NYSE: BSX) in connection with its patent infringement...
More news about: OrbusNeich Medical Inc. , Boston Scientific Corporation
- < Prev
1 of 1
- Next >
Modify your Search
 |
Quickly search for PR Newswire releases by adding our plugin to your browser search |